Axsome Therapeutics (AXSM) Other Operating Expenses (2020 - 2026)

Axsome Therapeutics has disclosed Other Operating Expenses across 7 years of filings, most recently posting $16.9 million for Q1 2026.

• Other Operating Expenses for Q1 2026 came in at $16.9 million, up 31.18% year-over-year; the trailing twelve-month figure through Mar 2026 was $101.6 million (up 36.87% YoY), and the FY2025 annual result was $51.4 million, down 24.24% from the prior year.
• Other Operating Expenses came in at $16.9 million for Q1 2026 at Axsome Therapeutics, down from $51.1 million in the prior quarter.
• In the past five years, Other Operating Expenses ranged from a high of $52.2 million in Q4 2023 to a low of -$45.3 million in Q3 2022.
• The 5-year median for Other Operating Expenses is $12.0 million (2023), against an average of $13.1 million.
• Across the five-year window, Other Operating Expenses plunged 100.03% in 2022 and surged 90170.07% in 2023, its largest moves.
• Axsome Therapeutics' Other Operating Expenses stood at -$57946.0 in 2022, then soared by 90170.07% to $52.2 million in 2023, then slumped by 55.73% to $23.1 million in 2024, then surged by 120.98% to $51.1 million in 2025, then slumped by 66.93% to $16.9 million in 2026.
• The last three Other Operating Expenses figures came in at $16.9 million (Q1 2026), $51.1 million (Q4 2025), and $26.7 million (Q3 2025), per Business Quant data.